AU2002226752A1 - Substituted carbostyril derivatives as 5-HT1A receptor subtype agonists - Google Patents

Description

5-HT_1A RECEPTOR SUBTYPE AGONIST

BACKGROUND OF THE INVENTION FIELD OF THE INVENTION

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with the 5-HT_1A receptor subtype. The active ingredient comprise a carbostyril derivative or a salt thereof. RELATED ART

U.S. Patent No. 5,006,528; European Patent No. 367,141 and Japanese Patent Kokai (Laid-open) 7- 304,740 (1995) contain the same chemical structural formula as the carbostyril derivatives in the present invention, and their pharmacological properties are beneficial drug treatments for schizophrenia. Carbostyril compounds, as well as those disclosed in Japanese Patent Kokai (Laid-open) 9-301, 867 (1997) are useful for the treatment of anxiety.

The carbostyril derivatives disclosed in European Patent No. 226,441 have the genus of the carbostyril derivatives in the present invention, and they are useful for the treatment of hypoxia.

In addition to the above, the carbostyril derivatives disclosed in U.S. Patent No. 4,734,416; Canadian Patent No. 1,117,110; British Patent No. 2,017,701; German Patent Nos. 2,911,108, 1,912,105 and 2,953,723; Japanese Patent Kokai (Laid-open) Nos. 54- 130,587 (1979), 55-127,371 (1980) and 62-149,664 (1987) have the genus of the carbostyril derivatives in the present invention, and they have antihistaminic activities and central nervous controlling activities. It is reported that aripiprazole (7-{4-[4- (2, 3-dichlorophenyl) -1-piperazinyl] butoxy}-3, 4-dihydro- carbostyril, also known as, OPC-14597, BMS-337,039 and OPS-31) binds with high affinity to dopamine D₂ receptors and with moderate affinity to dopamine D₃ and 5-HT₇ receptors (Masashi Sasa et al . , CNS Drug Reviews, Vol. 3, No. 1, pp. 24-33) .

Further, it is reported that aripiprazole possesses presynaptic dopaminergic autoreceptor agonistic activity, postsynaptic D₂ receptor antagonistic activity, and D₂ receptor partial agonistic activity (T. Kikuchi, K. Tottori, Y. Uwahodo, T. Hirose, T. Miwa, Y. Oshiro and S. Morita: J. Pharmacol. Exp. Ther., Vol. 274, pp. 329, (1995); T. Inoue, M. Domae, K. Yamada and T. Furukawa: J. Pharmacol. Exp. Ther., Vol. 277, pp. 137, (1996)).

However, it has not been reported that compounds in the present invention have agonistic activity at 5-HT_1A receptor subtype. It has been reported that therapeutic interventions using 5-HT_1A receptor ligands may be useful drug treatments for alcohol abuse (Mark Kleven et al., European Journal of Pharmacology, Vol. 281, ( 1995 ) pp . 219-228 ) .

It is also reported that 5-HT_1A agonist drugs may be useful for the treatment and/or prophylaxis of disorders associated with neuronal degeneration result- ing from ischemic events in mammals (U.S. Patent No. 5,162,375) .

It is also reported that 5-HT_1A receptor hypersensitivity could be the biological basis for the increased frequency of migraine attack in stressful and anxious conditions (Massimo Leone et al . , Neuro Report, Vol. 9, pp. 2605-2608(1998)).

It has recently been reported that (-)-(R)-2- [4- [ [ (3, 4-dihydro-2H-l-benzopyran-2-yl)methyl] amino] - butyl] -1, 2-benzisothiazol-3 (2H) -one 1, 1-dioxide monohydrochrolide (BAY-3702) , a 5-HT_1A receptor agonist, has neuroprotective, anxiolytic- and antidepressant- like effects in animal models (Jean De Vry et al., European Journal of Pharmacology, Vol. 357, (1998), pp. 1-8) . It is also reported that 5-HT_1A receptor agonists appear to be broad spectrum antiemetic agents (Mary C. Wolff et al . , European Journal of Pharmacology, Vol. 340, (1997), pp. 217-220; AB Alfieri et al., British Journal of Cancer, (1995), Vol. 72, pp. 1013-1015; Mary C. Wolff et al., Pharmacology

Biochemistry and Behavior, 1995, Vol. 52, No. 3, pp. 571-575; James B. Lucot, European Journal of Pharmacology, 1997, Vol. 253, pp. 53-60). Serotonin plays a role in several neurological and psychiatric disorders, including Alzheimer's disease, depression, nausea and vomiting, eating disorders, and migraine. (See Rasmussen et al., "Chapter 1. Recent Progress in Serotonin 5HT_1A Receptor Modulators", in Annual Reports in Medicinal Chemistry, Vol. 30, Section I, pp. 1-9, 1995, Academic Press, Inc.). WO 00/16777 discloses that a 5HT_1A receptor agonist, buspirone is efficacious in treating a variety of symptoms associated with ADHD, and that combined use of a D2 receptor agonist and 5-HT_1A agonist provides effective treatments for ADHD and Parkinson's disease. 5HT_1A agonists are effective in the treatment of cognitive impairment in Alzheimer's disease, Parkinson's disease or senile dementia. US 5824680 discloses that a 5-HT_1A agonist, ipsapirone, is effective in treating Alzheimer's disease by improving memory. US 4687772 describes that a 5-HT_1A partial agonist, buspirone, is useful for improving short term memory in patients in need of treatment. WO 93/04681 discloses that use of 5-HT_1A partial agonists have been used for the treatment or prevention of cognitive disorders associated with Alzheimer's disease, Parkinson's disease or senile dementia. 5HT_1A agonists are also effective in the treatment of depression. US 4771053 describes that a 5-HT_1A receptor partial agonist, gepirone, is useful in alleviation of certain primary depressive disorders, such as severe depression, endogenous depression, major depression with melancholia, and atypical depression. WO 01/52855 discloses that the combined use of the 5- HT_1A receptor partial agonist gepirone with an antidepressant can effectively treat depression.

The 5-HT_1A receptor partial agonist buspirone alleviates motor disorders such as neuroleptic induced parkinsonism and extrapyramidal symptoms. These observations are disclosed in US 4438119. Furthermore 5-HT_1A agonists reverse neuroleptic-induced catalepsy in rodents, which mimic movement impairments observed in Parkinson's disease (Mark J. Millan, Journal of Pharmacology and Experimental Therapeutics, 2000, Vol. 295, p853-861) . Thus, aripiprazole can be used to manage psychosis in geriatric patients, Alzheimer's disease, Parkinson' s disease or senile dementia, since it possesses potent, partial agonistic activities at D₂ and 5-HT_1A receptors. In addition, these patients might not experience extrapyramidal symptoms due to this property of aripiprazole.

Heretofore, schizophrenia is understood to be caused by hyperactivity in the brain dopa inergic system. For this reason, some drugs were developed with strong dopaminergic receptor blocking activity. These typical antipsychotic drugs are effective in the treatments for the positive symptoms of schizophrenia, which include hallucinations, delusions and the like. During the last decade, a variety of atypical anti- psychotic drugs have been developed, which include clozapine, risperidone, olanzapine, quetiapine. These drugs have less extrapyramidal side effects, and have other activities in addition to their DA-receptor blocking activities. In contrast to typical antipsychotic drugs, such as chlorpromazine, haloperidol, etc., it is reported that atypical antipsychotic drugs are more effective against the negative symptoms and cognitive impairments associated with schizophrenia than typical antipsychotic drugs, and atypical antipsychotic drugs also have less extrapyramidal side effects (S. Miyamoto, G. E. Duncan, R. B. Mailman and J. A. Lieberman: Current Opinion in CPNS Investiga- tional Drugs, Vol. 2, pp. 25, (2000)). However, even though atypical antipsychotic drugs provide a suitable pharmacotherapy for schizophrenia, certain patients are resistant to the antipsychotic therapies of these drugs. These patients may either not respond or may become refractory (i.e. may feel more anxious, depressed or cognitive dysfunction) in response to antipsychotic therapy. These treatment-resistant patients pose a problem for how a physician may provide an appropriate therapy.

At present, a number of treatment-resistant and treatment-refractory schizophrenic patients display symptoms that do not respond adequately to a variety of known effective classes and doses of typical or atypical antipsychotic drugs. Furthermore, these patients may also be inveterate schizophrenia or chronic schizophrenics who are often repeatedly admitted to and discharged from hospitals (R. R. Conely and R. W. Buchanan: Schizophr. Bull., Vol. 23, pp. 663, (1997) ) .

Symptoms of patients corresponding to treatment-resistant and treatment-refractory schizophrenics involve not only the positive symptoms, but also the negative symptoms and emotional disorders, as well as cognitive impairments (i.e., cognitive dysfunction or cognitive disturbances) (K. Akiyama and S. Watanabe: Jpn. J. Clin. Psychopharmacol . , Vol. 3, pp. 423, (2000) ) .

Cognitive impairment exists separately from the psychic symptoms in a schizophrenic individual. Thus, medical treatment is therefore quite important, because the cognitive impairment may disturb the socially adaptable behavior of these individuals (C. Hagger, P. Buckley, J. T. Kenny, L. Friedman, D. Ubogy and H. Y. Meltzer: Biol. Psychiatry, Vol. 34, pp. 702, (1993); T. Shar a and D. Mockler: J. Clin. Psychopharmacol., Vol. 18, (Suppl. 1), pp. 128, (1998)).

At present, clozapine is an antipsychotic drug that is effective against treatment-resistant schizophrenia. Clozapine (marketed under the name of Clozaril) was approved in 1990 by FDA for the treatment and management of severely ill schizophrenics who failed to respond adequately to standard antipsychotic therapy (M. W. Jann: Pharmacotherapy, Vol. 11, pp. 179, (1991) ) . Clozapine has been reported to be effective against cognitive impairments in treatment-resistant schizophrenics (C. Hagger, P. Buckley, J. T. Kenny, L. Friedman, D. Ubogy and H. Y. Meltzer: Biol. Psychiatry, Vol. 34, pp. 702, (1993); M. A. Lee, P. A. Thompson and H. Y. Meltzer: J. Clin. Psychiatry, Vol. 55 (Suppl. B) , pp. 82, (1994); D. E. M. Fujii, I. Ahmed, M. Jokumsen and J. M. Co pton: J. Neuropsychiatry Clin. Neurosci., Vol. 9, pp. 240, (1997)). For example, it is reported that clozapine improves cognitive impairments in attention, response time, fluent-speech, etc. in treatment-resistant schizophrenics (M. A. Lee, P. A. Thompson and H. Y. Meltzer: J. Clin. Psychiatry, Vol. 55 (Suppl. B), pp. 82, (1994)). It has been also reported that clozapine provides effective improvements in cognitive impairments in an objective evaluation scale of the Wechsler Adult Intelligence Scale-Revised Full Scale (D. E. M. Fujii, I. Ahmed, M. Jokumsen and J. M. Compton: J. Neuropsychiatry Clin. Neurosci., Vol. 9, pp. 240, (1997) ) .

The 5-HT_1A receptor has been demonstrated to play a role in the therapeutic efficacy of .clozapine against treatment-resistant schizophrenia and cognitive impairments. This relation ship was revealed by a binding experiment using human the 5-HT_1A receptors (S. L. Mason and G. P. Reynolds: Eur. J. Pharmacol., Vol. 221, pp. 397, (1992)). Further, in accordance with progress in molecular pharmacology, it is clearly understood that 5-HT_1A receptor agonistic activity or 5-HT_1A receptor partial agonistic activity plays an important role in treatment-resistant schizophrenia and cognitive impairments (A. Newman-Tancredi, C. Chaput, L. Verriele and M. J. Millan: Neuropharmacology, Vol. 35, pp. 119, (1996)). Additionally, it was reported that the number of 5-HT_1A receptor is increased in the prefrontal cortex of chronic schizophrenics who were classified treatment-resistant. This observation was explained by a compensatory process where by the manifestation of severe symptoms of chronic schizophrenia are a result of impaired neuronal function mediated by hypofunctional 5-HT_1A receptors (T. Hashimoto, N. Kitamura, Y. Kajimoto, Y. Shirai, 0.

Shirakawa, T. Mita, N. Nishino and C. Tanaka: Psycho- pharmacology, Vol. 112, pp. S35, (1993)). Therefore, a lowering in neuronal transmission mediated through 5- HT_1A receptors is expected in treatment-resistant schizophrenics. Thus the clinical efficacy of clozapine may be related to its partial agonist efficacy at the 5-HT_1A receptors (A. Newman-Tancredi, C. Chaput, L. Verriele and M. J. Millan: Neuropharmacology, Vol. 35, pp. 119, (1996)). 5-HT_1A receptor agonistic activity may be related to the clinical effects of clozapine, and this hypothesis is supported by a positron emission tomography study in primates which showed that clozapine interacts with brain 5-HT_1A receptors at a therapeutically effective dose (Y. H. Chou, C. Halldin and L. Farde: Int. J. Neuropsycho- pharmacol. , Vol. 4 (Suppl. 3), pp. S130, (2000)). Furthermore tandospirone, which is known as a selective 5-HT_1A receptor agonist, improved cognitive impairments in chronic schizophrenic patients (T. Sumiyoshi, M. Matsui, I. Ya ashita, S. Nohara, T. Uehara, M. Kurachi and H. Y. Meltzer: J. Clin. Pharmacol., Vol. 20, pp. 386, (2000) ) . While, in animal tests, all reports do not always suggest that 5-HT_1A receptor agonist activity may be related to cognitive impairment, however, 8-OH- DPAT (8-hydroxy-2- (di-n-propylamino) tetralin) , which is known as a selective 5-HT_1A receptor agonist, improves learning and memory impairments induced by scopolamine known as a muscarinic receptor antagonist, suggesting a relationship between 5-HT_1A receptor agonistic activity and improvements in cognitive impairments (M. Carli, P. Bonalu i, R. Samanin: Eur. J. Neurosci., Vol. 10, pp. 221, (1998); A. Meneses and E. Hong: Neurobiol . Learn. Mem., Vol. 71, pp. 207, (1999)).

Atypical antipsychotic drugs, such as risperidone and olanzapine, were marketed after clozapine, and it is reported that these drugs improve treatment-resistant schizophrenia or cognitive i pair- ments in treatment-resistant schizophrenics (M. F.

Green, B. D. Marshall, Jr., W. C. Wirshing, D. Ames, S. R. Marder, S. McGurck, R. S. Kern and J. Mintz: Am. J. Psychiatry, Vol. 154, pp. 799, (1997); G. Bondolifi, H. Dufour, M. Patris, J. P. May, U. Billeter, C. B. Eap and P. Baumann, on behalf of the risperidone Study Group: Am. J. Psychiatry, Vol. 155, pp. 499, (1998); A. Breier, S. H. Hamilton: Biol. Psychiatry, Vol. 45, pp. 403, (1999)).

In contrast to reports that clozapine was moderately effective against treatment-resistant schizophrenia, risperidone and olanzapine were not consistently superior to typical antipsychotic drugs in their effectiveness against treatment-resistant schizophrenia. Thus, risperidone and olanzapine bind with lower affinity to human 5-HT_1A receptors (S. Miyamoto, G. E. Duncan, R. B. Mailman and J. A. Lieberman: Current Opinion in CPNS Investigational Drugs, Vol. 2, pp. 25, (2000)), and as such these drugs can not clearly perform activities through human 5-HT_1A receptors at clinical effective doses.

Therefore, at present, it is understood that clozapine is effective against treatment-resistant schizophrenia (D. W. Bradford, M. H. Chakos, B. B.

Sheitman, J. A. Lieberman: Psychiatry Annals, Vol. 28, pp. 618, (1998); A. Inagaki : Jpn. J. Clin. Psycho- pharmacol., Vol. 3, pp. 787, (2000)).

As explained above, 5-HT_1A receptor agonistic activity is important for improving treatment-resistant schizophrenia or cognitive impairment caused by treatment-resistant schizophrenia. Clozapine is effective against treatment-resistant schizophrenia, however, its use is limited due to its severe side- effect of producing agranulocytosis which requires patients to undergo periodical blood tests. Under these circumstances, the development of a safe anti- psychotic drug with potent, full or partial agonist activity at 5-HT_1A receptors is earnestly desired. The carbostyril compound in the present invention binds with high affinity and displays a potent, partial agonist activity at the 5-HT_1A receptors and it has higher intrinsic activity (about 68%) as compared with that of clozapine. Therefore, the compound in the present invention has a 5-HT_1A receptor agonistic activity that is more potent than the agonistic activity of clozapine. Thus, the present carbostyril compound may represent a more potent and highly safe drug for curing treatment-resistant schizophrenia, cognitive impairments caused by treatment-resistant schizophrenia, inveterate schizophrenia, cognitive impairments caused by inveterate schizophrenia, chronic schizophrenia, cognitive impairments caused by chronic schizophrenia and the like, as compared with other currently available pharmacotherapeutic treatments. That is, the compound in the present invention may prove to be a potent and safer drug therapy for treatment-resistant schizophrenia, cognitive impairments caused by treatment-resistant schizophrenia, inveterate schizophrenia, cognitive impairments caused by inveterate schizophrenia, chronic schizophrenia, or cognitive impairments caused by chronic schizophrenia, etc., which fail to respond adequately to currently available antipsychotic drugs such as chlorpromazine, haloperidol, sulpiride, fluphenazine, perphenazine, thioridazine, pimozide, zotepine, risperidone, olanzapine, quetiapine, amisulpride, etc.

In particular, the carbostyril compound in the present invention may be a potent and highly safe drug therapy against treatment-resistant schizophrenia, cognitive impairments caused by treatment-resistant schizophrenia, inveterate schizophrenia, cognitive impairments caused by inveterate schizophrenia, chronic schizophrenia or cognitive impairments caused by chronic schizophrenia, etc. which fail to respond adequately to both of 1 to 3 typical antipsychotic drugs selected from the group consisting of chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from the group consisting of risperidone, olanzapine, quetiapine and amisulpride.

Moreover, the compound in the present invention may be a potent and highly safe drug therapy against treatment-resistant schizophrenia, cognitive impairments caused by treatment-resistant schizophrenia, inveterate schizophrenia, cognitive impairment caused by inveterate schizophrenia, chronic schizophrenia or cognitive impairment caused by chronic schizophrenia, etc. which fail to respond adequately to both of 2 typical antipsychotic drugs selected from the group consisting of chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from the group consisting of risperidone, olanzapine, quetiapine and amisulpride.

Moreover, the compound in the present invention may be a potent and highly safe drug therapy against treatment-resistant schizophrenia, cognitive impairments caused by treatment-resistant schizophrenia, inveterate schizophrenia, cognitive impairments caused by inveterate schizophrenia, chronic schizophrenia, cognitive impairments caused by chronic schizophrenia, etc. which fail to respond adequately to both of 1 to 2 typical antipsychotic drugs selected from the group consisting of chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from the group consisting of risperidone, olanzapine, quetiapine and amisulpride. Moreover, the compound in the present invention may be a potent and highly safe drug therapy against treatment-resistant schizophrenia, cognitive impairments caused by treatment-resistant schizophrenia, inveterate schizophrenia, cognitive impairment caused by inveterate schizophrenia, chronic schizophrenia or cognitive impairment caused by chronic schizophrenia, etc. which fail to respond adequately to both of 2 typical antipsychotic drugs selected from the group consisting of chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from the group consisting of risperidone, olanzapine, quetiapine and amisulpride.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a method of treating a patient suffering from a disorder of the central nervous system associated with the 5-HT_1A receptor subtype.

DETAILED DESCRIPTION OF THE INVENTION

As the 5-HT_1A receptor subtype agonist compound for use in accordance with the present invention, carbostyril derivatives represented by the following formula (1) are used:

wherein the carbon-carbon bond between 3- and 4- positions in the carbostyril skeleton is a single or a double bond .

The compounds of the forgoing general formula ( 1 ) are known compounds , which are disclosed in publication such as U . S . Pat . No . 5, 006, 528 or which can be readily prepared by the processes described in the above publication.

The carbostyril derivative represented by the formula (1) in the present invention can easily be converted into its acid-addition salt by reacting it with a pharmaceutically acceptable acid. Examples of such acid include inorganic acids, such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; organic acids, such as oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid and the like.

The solvent of solvates is a solvent conventionally used in recrystallization. Examples of solvates include hemihydrates, hydrates, and alco- holates, such as ethanolates, methanolates, isopropanolates and the like.

The desired compounds, prepared by the reactions mentioned above, can easily be isolated and purified by usual separation procedures such as solvent extraction, dilution, recrystallization, column chromatography, preparative thin layer chromatography and the like.

The potent, partial 5-HT_1A receptor agonist in the present invention is useful for various disorders of the central nervous system associated with the 5-HT_1A receptor subtype that induces bipolar disorders, such as bipolar I disorder with most recent hypomanic, manic, mixed, depressed or unspecified episode; bipolar II disorder with recurrent major depressive episodes with hypomanic episodes, and cyclothymic disorder; depression, such as endogenous depression, major depression, melancholia, and treatment-resistant depression; panic disorder; obsessive compulsive disorder (OCD) ; sleep disorders; sexual dysfunction; alcohol abuse and drug addiction; cognitive impairment; neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and the like, cognitive impairments caused by neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and related disorders; emesis; motion sickness; obesity; migraine; autism; Down's syndrome; attention-deficit hyper- activity disorder (ADHD) ; treatment-resistant, inveterate or chronic schizophrenia, (which fail to respond adequately to currently available antipsychotic drugs) ; cognitive impairments caused by treatment- resistant schizophrenia, inveterate schizophrenia or chronic schizophrenia, and the like. Compounds of the present invention may be suitably prepared into pharmaceutically acceptable formulations (see U.S. Patent No. 5,006,528, European Patent No. 367,141 and Japanese Kokai (Laid-open) 7- 304,740 (1995), and Japanese Patent Application No. 2000-194976 incorporated by reference herein) .

The dosage of these pharmaceutical preparations of the invention may be selected appropriately depending on the method of administration, the patient's age, sex and other factors, severity of the disease and other factors. Generally, however, the daily dose of the active ingredient compound is preferably within the range of about 0.0001 to about 50 mg per kilogram of body weight. It is desirable that the active ingredient compound be contained in each unit dosage form in an amount of about 0.001 to about 1,000 mg, particularly 0.01 to 100 mg, more particularly 0.1 to 50 mg, yet more particularly 1 mg to 20 mg.

Pharmacological tests

1. MATERIALS AND METHODS

1.1 Test Compound

7- { 4- [4- (2, 3-Dichlorophenyl) -1-piperazinyl] - butoxy} -3, 4-dihydrocarbostyril (aripiprazole) was used as test compound.

1.2 Reference Compounds

Serotonin (5-HT) and WAY-100635 (N-[2-[4-(2- methoxyphenyl) -1-piperazinyl] ethyl] -N- (2-pyridimyl) - cyclohexanecarboxamide, a 5-HT_1A receptor antagonist, manufactured by RBI (Natick, MA) were used as reference compounds .

1.3 Vehicle

Dimethyl sulfoxide (DMSO) manufactured by Sigma Chemical Co. (St. Louis, MO) was used as vehicle.

1.4 Preparation of Test and Reference Compounds

Test compound was dissolved in 100% dimethyl sulfoxide (DMSO) to yield 100 μM stock solutions (final concentration of DMSO in all tubes containing test compound was 1%, v/v) . All other reference compounds were prepared by the same method using double-distilled water rather than DMSO.

1.5 Experimental Procedure for the [³⁵S]GTP_yS Binding Assay

Test and reference compounds were studied in triplicate at 10 different concentrations (0.01, 0.1, 1, 5, 10, 50, 100, 1000, 10000 and 50000 nM) for their effects upon basal [³S]GTP_yS binding to h5-HT_1A CHO cell membranes. Reactions were performed in 5 ml glass test tubes containing 8 μl of test/reference drug mixed with 792 μl of buffer (25 mM Tris HCl, 50 mM NaCl, 5 mM MgCl₂, 0.1 mM EGTA, pH = 7.4) containing GDP (1 μM) ,

[³⁵S]GTP_γS (0.1 nM) and h5-HT_1A CHO cell membranes (10 μg protein/reaction; NEN Life Science Products, Boston, MA; catalog # CRM035, lot # 501-60024, GenBank # X13556) . . Reactions proceeded for 60 min at room temperature and were terminated by rapid filtration through Whatman GF/B filter paper, using a Brandel harvester and 4x3 ml ice-cold buffer washes. ³⁵S radioactivity bound to the filter paper was measured using liquid scintillation counting (1272 Clinigamma, LKB/Wallach) .

1.6 Experimental Procedure to Determine the Binding Affinity of Test compound (aripiprazole) at the h5-HT_1A Receptor Test compound was studied in triplicate at 10 different concentrations (0.01, 0.1, 1, 10, 50, 100, 500, 1000, 5000 and 10000 nM) to determine its displacement of [³H] 8-OH-DPAT (1 nM; NEN Life Sciences; catalog # NET 929, lot # 3406035, Specific Activity = 124.9 Ci/mmol) binding to h5-HT_1A receptors in CHO cell membranes (15 - 20 μg protein; NEN Life Science Products, catalog # CRM035, lot # 501-60024) . Membranes (396 μl) were incubated in 5 ml glass tubes containing [³H] 8-OH-DPAT (396 μl) , test compound or vehicle (8 μl) and buffer A (50 mM Tris.HCl, 10 mM MgS0₄, 0.5 mM EDTA, 0.1% (w/v) ascorbic acid, pH = 7.4). All assays proceeded for 60 min at room temperature and were terminated by rapid filtration through Whatman GF/B filter paper (presoaked in buffer B; 50 mM

Tris.HCl, pH = 7.4), using a Brandel harvester and 4x1 ml ice-cold washes with buffer B. Non-specific binding was determined in the presence of 10 μM (+) 8-OH-DPAT. 1.7 Parameters Determined Serotonin (5-HT) is a full 5-HT_1A receptor agonist which stimulates increases in basal [³⁵S]GTP_yS binding to h5-HT_1A receptors in recombinant CHO cell membranes. Test compound was studied at 10 concentrations to determine their effects upon basal [³⁵S]GTP_γS binding relative to that produced by 10 μM 5-HT. The relative potency (EC₅₀, 95% confidence interval) and intrinsic agonist activity (% of E_m-_X for 10 μM 5-HT) was calculated for each compound by computerized non-linear regression analysis of complete concentration-effect data. The binding affinity of test compound at the h5- HT_1A receptor was determined by its ability to prevent [³H] 8-OH-DPAT binding to CHO cell membranes that express this receptor. Non-linear regression analysis of the competition binding data was used to calculate an inhibition constant (IC₅₀, 95% confidence interval) , which is the concentration of test compound that occupies half of the h5-HT_1A sites specifically bound by [³H] 8-OH-DPAT. The affinity of h5-HT_1A receptors for test compound (Ki, 95% confidence interval) was calculated by the equation, Ki = (IC₅₀) / (1+ ([ [³H] 8-OH- DPAT] /Kd) , where the Kd for [³H] 8-OH-DPAT at h5-HT_1A = 0.69 nM (NEN Life Sciences). All estimates of drug binding affinity, potency and intrinsic efficacy at the h5-HT_1A receptor were calculated using GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, CA) .

2. RESULTS Test compound and 5-HT produced concentration-dependent increases above basal [³⁵S]GTP_γS binding. 1% DMSO tested alone had no effect upon basal or drug-induced [³⁵S]GTP_γS binding.

Test compound (EC₅₀ = 2.12 nM) , 5-HT (EC₅₀ = 3.67 nM) , potently stimulated basal [³⁵S]GTP_yS binding. Potency and intrinsic agonist efficacy estimates were derived by non-linear regression analysis with correla- tion coefficients (r²)>0.98 in each case (Table 1). Test compound exerted partial agonist efficacies in the 65 - 70% range. WAY-100635 produced no significant change (unpaired Student's t-test) in basal [³⁵S]GTP_γS binding at all concentrations tested (Table 1) . WAY- 100635 did, however, completely inhibit the effects of 5-HT and test compound upon [³⁵S]GTP_yS binding to h5-HT_1A receptors in CHO cell membranes (Table 2) . Tables 1 and 2 are shown below. Test compound demonstrated high affinity binding to h5-HT_1A receptors in CHO cell membranes (IC₅₀ = 4.03 nM, 95% confidence interval = 2.67 to 6.08 nM; Ki = 1.65 nM, 95% confidence interval = 1.09 to 2.48 nM) .

Table 1 Potency (EC₅₀) and Intrinsic Agonist Efficacy

(E_raax) of Test compound and Reference Drugs in a h5-HT_1A [³⁵S]GTP_γS CHO-cell Membrane Binding Assay.

Table 2 Inhibitory Potency (IC₅₀) of WAY-100635 versus 1 μM Concentration of 5-HT and Test compound in a h5-HT_1A [³⁵S]GTP_γS CHO-cell Membrane Binding Assay.

Claims (32)

1. CLAIMS 1. Use of a compound for the production of a medicament for treating a patient suffering from a disorder of the central nervous system associated with 5-HT_1A receptor subtype, which the medicament comprises a therapeutically effective amount of a carbostyril compound of formula (1) :

   wherein the carbon-carbon bond between 3- and 4- positions in the carbostyril skeleton is a single or a double bond; and a pharmaceutically acceptable salt or solvate thereof.
2. 2. The use of Claim 1 wherein the disorder is depression.
3. 3. The use of Claim 1 wherein the disorder is treatment-resistant schizophrenia, treatment-resistant schizophrenia with cognitive impairments, inveterate schizophrenia, inveterate schizophrenia with cognitive impairments, chronic schizophrenia, or chronic schizophrenia with cognitive impairments.
4. 4. The use of Claim 3 wherein the disorder is treatment-resistant schizophrenia, inveterate schizophrenia or chronic schizophrenia, which fails to respond adequately to currently available antipsychotic drugs .
5. 5. The use of Claim 3 wherein the disorder is treatment-resistant schizophrenia with cognitive impairments, inveterate schizophrenia with cognitive impairments or chronic schizophrenia with cognitive impairments, which fails to respond adequately to currently available antipsychotic drugs.
6. 6. The use of Claim 4 wherein the currently available antipsychotic drugs are chlorpromazine, haloperidol, sulpiride, fluphenazine, perphenazine, thioridazine, pimozide, zotepine, risperidone, olanzapine, quetiapine, or amisulpride.
7. 7. The use of Claim 5 wherein the currently available antipsychotic drugs are chlorpromazine, haloperidol, sulpiride, fluphenazine, perphenazine, thioridazine, pimozide, zotepine, risperidone, olanzapine, quetiapine, or amisulpride.
8. 8. The use of Claim 4 wherein the currently available antipsychotic drugs are 1-3 typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
9. 9. The use of Claim 5 wherein the currently available antipsychotic drugs are 1-3 typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
10. 10. The use of Claim 4 wherein the currently available antipsychotic drugs are two typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
11. 11. The use of Claim 5 wherein the currently available antipsychotic drugs are two typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
12. 12. The use of Claim 4 wherein the currently available antipsychotic drugs are one to two typical antipsychotic drugs selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
13. 13. The use of Claim 5 wherein the currently available antipsychotic drugs are one to two typical antipsychotic drugs selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
14. 14. The use of Claim 4 wherein the currently available antipsychotic drugs are two typical antipsychotic drug selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride .
15. 15. The use of Claim 5 wherein the currently available antipsychotic drugs are two typical antipsychotic drug selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
16. 16. The use of Claim 1 wherein the disorder is autism, Down's syndrome, or attention deficit hyper- activity disorder (ADHD) .
17. 17. The use of Claim 1 wherein the disorder is a neurodegenerative disease.
18. 18. The use of Claim 17 wherein the neurodegenerative disease is Alzheimer' s disease or Parkinson's disease.
19. 19. The use of Claim 1 wherein the disorder is panic, obsessive compulsive disorder (OCD) , sleep disorders, sexual dysfunction, alcohol and drug addiction, eme.sis, motion sickness, obesity or migraine.
20. 20. The use of Claim 1-19 wherein the carbostyril compound is 7-{4- [4- (2, 3-dichlorophenyl) -1- piperazinyl]butoxy}-3, 4-dihydrocarbostyril .
21. 21. The use of claim 1 wherein the disorder is depression, such as endogenous depression, major depression, melancholia or treatment-resistant depression; sexual dysfunction; alcohol abuse and drug addiction; cognitive impairments; neurodegenerative diseases, such as Alzheimer's disease or Parkinson's disease; autism; attention deficit hyperactivity disorder (ADHD) ; cognitive impairment caused by treatment-resistant schizophrenia, cognitive impairment caused by inveterate schizophrenia, or cognitive impairment caused by chronic schizophrenia.
22. 22. The use of claim 1 wherein the disorder is depression, such as endogenous depression, major depression, melancholia or treatment-resistant depression.
23. 23. The use of claim 1 wherein the disorder is cognitive impairment caused by treatment-resistant schizophrenia, cognitive impairment caused by inveterate schizophrenia, cognitive impairment caused by chronic schizophrenia.
24. 24. The use of claim 23 wherein the disorder is cognitive impairment caused by treatment-resistant schizophrenia, cognitive impairment caused by inveterate schizophrenia, cognitive impairment caused by chronic schizophrenia, which fails to respond adequately to currently available antipsychotic drugs.
25. 25. The use of claim 24 wherein the currently available antipsychotic drugs are chlorpromazine, haloperidol, sulpiride, fluphenazine, perphenazine, thioridazine, pimozide, zotepine, risperidone, olanzapine, quetiapine, or amisulpride.
26. 26. The use of claim 24 wherein the currently available antipsychotic drugs are 1-3 typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
27. 27. The use of claim 24 wherein the currently available antipsychotic drugs are two typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
28. 28. The use of claim 24 wherein the currently available antipsychotic drugs are one to two typical antipsychotic drugs selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
29. 29. The use of claim 24 wherein the currently available antipsychotic drugs are two typical antipsychotic drug selected from chlorpromazine and haloperidol, and one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.
30. 30. The use of claim 1 wherein the disorder is cognitive impairment caused by neurodegenerative disease.
31. 31. The use of claim 30 wherein the cognitive impairment caused by neurodegenerative disease is Alzheimer's disease or Parkinson's disease.
32. 32. The use of claims 21-31 wherein the carbostyril compound is 7-{4- [4- (2, 3-dichlorophenyl) -1- piperazinyl]butoxy}-3, 4-dihydrocarbostyril.